Skip to content

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
CTO
Citius Oncology, Inc.CTOR
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
6.1×+1.1×
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
3.3×+2.8×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
+1.8×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
2.2×-20.1×

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Calculated from TuHURA Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s cash ratio?
TuHURA Biosciences, Inc. (HURA) reported cash ratio of 1× in Q1 2026.
How has TuHURA Biosciences, Inc.'s cash ratio changed year-over-year?
TuHURA Biosciences, Inc.'s cash ratio decreased by 20.2% year-over-year, from 1.3× to 1×.
What is the long-term trend for TuHURA Biosciences, Inc.'s cash ratio?
Over 3 years (2022 to 2025), TuHURA Biosciences, Inc.'s cash ratio has grown at a -25.9% compound annual growth rate (CAGR), from 1.5× to 0.6×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.